Roche cleared over rep conduct complaint

pharmafile | September 23, 2011 | News story | Sales and Marketing ABPI Code of Practice, Roche 

Roche has been cleared by Code regulator the PMCPA of any wrongdoing after an NHS employee complained about the promotion of hepatitis C drug Pegasys (peginterferon alfa-2a).

Of particular concern to the complainant was that a Roche representative was married to the nurse specialist they believed to be responsible for choosing the treatment for hepatitis C in a large teaching hospital.

This rep received a cash bonus and a trip to the Caribbean – on which he took his wife – due to Pegasys’ sales performance, and the rep’s wife also received speaker fees from Roche.

But the PMCPA noted there would always be cases when a rep was married to a health professional, that the wife in this case did not influence patient medication, and that both had declared potential conflicts of interest to their respective employers.

Advertisement

While reminding companies that they should be aware of how their actions were perceived from outside, it said there was no evidence to show that the rep or Roche had breached the ABPI’s Code of Practice in any way.

Adam Hill

Related Content

Roche secures CE Mark for automated latent tuberculosis blood test

Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content